Robust evidence is needed in treating acne [4]

British Medical Journal

Volumn 325, Issue 7377, 2002, Pages 1422-

  Garner, Sarah ^a   Eady, Anne ^b   Avery, Tony ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOID; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ACNE; ACNE VULGARIS; ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; SIDE EFFECT; SKIN DISEASE;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PROPIONIBACTERIUM ACNES;

EID: 0037079402     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Webster GF. Acne vulgaris [with commentary by T Poyner and B Cunliffe]. BMJ 2002;325:475-9. (31 August.)
2. Department of Health. UK Antimicrobial Resistance Strategy and Action Plan. London: DoH, June 2001.www.doh.gov.uk/pdfs/arbstrat.pdf(accessed 18 Nov 2002).
3. Eady EA. Bacterial rcsistance in acne. Dermatology 1998;196:59-66.
4. Garner S. Acne vulgaris. In Williams H, Bigby M, Herxheimer A, Diepgen T, Naldi L, Rzany B, eds. Evidence-Based Dermatology. London: BMJ Books (in press).
5. Hoiby N, Jarlov JO, Kemp M, Tvede M, Bangsborg JM, Kjerulf A. et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997;349:167-9.